Printer Friendly

INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992

 INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME
 FOR THE SECOND QUARTER OF 1992
 NESS-ZIONA, Israel, Aug. 11 /PRNewswire/ -- InterPharm Laboratories Limited (NASDAQ: IPLLF) today reported revenues of US$12.4 million for the second quarter ending June 30, 1992, compared with $8.1 million for the same period last year, an increase of 52 percent.
 Revenues for the six months ending June 30, 1992, rose 46 percent to $23.4 million, compared with $16.0 million during the same period in 1991. Net income rose 62 percent to $2.9 million or 47 cents per share. This compares with $1.8 million or 29 cents per share for the six months of 1991.
 "Sales of FRONE(R) (human beta interferon) in Italy contributed to the increase in revenues and net income during this period. An important development this quarter was the registration of FRONE in Spain, for condyloma, and for Hepatitis B and C," said Dr. Yoram Karmon, InterPharm's president and CEO.
 InterPharm Laboratories Ltd. is a member of The Ares-Serono Group, a worldwide developer and marketer of pharmaceutical and diagnostic products, with executive headquarters in Geneva, Switzerland and operational headquarters in Boston, Mass. InterPharm's shares are traded over-the-counter in the U.S.
 Following is a summary of unaudited comparative results (all amounts are in US dollars.
 INTERPHARM LABORATORIES
 Three months ended Six months ended
 6/30/92 6/30/91 6/30/92 6/30/91
 Net revenues $12,365,011 $8,124,977 $23,417,829 $16,018,777
 Operating profit 1,233,500 883,210 2,693,664 1,793,818
 Financial (expense)
 income net (161,505) 6,747 (82,310) 19,536
 Net income 1,119,605 889,957 2,935,150 1,813,354
 Earnings per share 18 cents 14 cents 47 cents 29 cents
 Weighted average
 number of shares
 outstanding 6,242,385 6,240,242 6,242,385 6,238,821
 -0- 8/11/92
 /CONTACT: Gina Cella of Ares-Serono Inc., 617-982-9000, ext. 251/
 (IPLLF) CO: InterPharm Laboratories; Ares-Serono Inc. ST: Massachusetts IN: MTC SU: ERN


PB -- NE006 -- 8851 08/11/92 09:37 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:352
Previous Article:OSTEOTECH SIGNS AGREEMENT FOR REVOLUTIONARY PLASMA TISSUE STERILIZATION TECHNOLOGY
Next Article:CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS OF NOVEL ANTI-STROKE COMPOUND
Topics:


Related Articles
INTERPHARM LABORATORIES REPORTS 1991 THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
INTERPHARM LABORATORIES REPORTS AN INCREASE IN SALES AND NET INCOME IN 1991
INTERPHARM LABORATORIES LTD. REPORTS THIRD QUARTER AND NINE MONTHS EARNINGS AND INCOME
INTERPHARM LABORATORIES LTD. REPORTS 1993 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND NET INCOME FOR THE SECOND QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND INCOME FOR THE THIRD QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS 1993 RESULTS OF OPERATIONS
INTERPHARM LABORATORIES LIMITED REPORTS 1994 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LIMITED REPORTS A NEGATIVE IMPACT ON SALES OF FRONE IN ITALY
INTERPHARM LABORATORIES LIMITED REPORTS 1994 SECOND QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters